Liquid Biopsy Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026

The global liquid biopsy market is anticipated to value over US$ 8.4 billion by the end of 2026 and expanding at a CAGR of over 20% during the forecast period, 2019 to 2026. Cancer is one of the most prevalent diseases owing to which the need for various cancer treatments. Techniques like biopsy are used to understand the tumour nature so that cancer can be managed correctly which can be eliminated eventually.

Liquid Biopsy Market Global Trends, Market Share, Industry Size, Growth,
Opportunities, and Market Forecast 2019 to 2026
The global liquid biopsy market is anticipated to value over US$ 8.4 billion by the end of 2026
and expanding at a CAGR of over 20% during the forecast period, 2019 to 2026.
Cancer is one of the most prevalent diseases owing to which the need for various cancer
treatments. Techniques like biopsy are used to understand the tumour nature so that cancer
can be managed correctly which can be eliminated eventually. There are two techniques used,
one is the conventional method of solid tissue biopsy and other is the newly introduced liquid
biopsy technique. Metastatic relapse evaluation and minimal invasiveness are some of the
advantages of using liquid biopsy over solid tissue biopsy which would increase its demand
resulting in the growth of the market. A further boost to the market growth will be contributed
by factors like patient preference to get minimally invasive therapy, increase in the number of
cancer cases and increase in the disposable income among patients suffering from cancer. Also,
using liquid biopsy tests to identify and treat rare cancers will provide multiple opportunities
for key market players to establish and expand their business.
Request a Sample Report @ https://www.futurewiseresearch.com/requestsample.aspx?id=203&page=requestsample
Insights on Global Liquid Biopsy Market:
By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Rest of the World
North America is the major shareholder of the global market as it has a high adoption rate of
liquid biopsy test and thus is expected to show a higher market growth rate during the forecast
period. Europe follows North America and it is primarily dominated by the UK, France and
Germany. The market spaces with the most number of opportunities for manufacturers are the
Asia Pacific and Latin America as these markets are yet to explored and penetrated properly.
These regions will, therefore, experience a higher market growth rate during the forecast
period. Rest of the World possesses a small share of the global market due to limited adoption.
By Circulating Biomarker
• Circulating tumour DNA
• Circulating Tumour Cells (CTC)
• Extracellular Vesicles
• Others
Circulating tumour DNA is one of the most analysed biomarkers due to its capability of
detecting cancer in earlier stages and prediction of cancer recurrence. CT-DNA and a
combination of various biomarker analysis have provided sensitivity ranging from 69% to 98%
for five different types of cancer according to a study by Cohen et al. These are the reasons that
this market segment will receive good traction during the forecast period. Exosomes, which are
small vesicles, were thought to be as waste disposal units initially. But recent researches
suggest that they play an important role in the initiation of cancer and also in its progression
and metastasis. Due to this new revelation, this market segment will get a significant amount of
traction during the forecast period and especially in the developed economy market regions
like North America and Europe as they adopt newer technologies with ease.
Purchase a Copy of this Premium Research Report At:
https://www.futurewiseresearch.com/request-sample.aspx?id=203&page=askfordiscount
By End User
• Hospitals
• Cancer Research Centres
• Diagnostic Laboratories
Hospitals dominate this market segment due to the provision of advanced infrastructure and
introduction of multi-speciality hospitals. It is expected that they will dominate the global
market in the forecast period as well.
Competitive Landscape:
• Biocept Inc.
• Qiagen Corp.
• Roche Diagnostics
• RainDance Technologies
Biocept’s Target Selector liquid biopsy follows all the clinical regulations listed by the National
Comprehensive Cancer Network (NCCN) and thus focusses on clinically-actionable cancer
biomarkers that will lead to an efficient tumour identification and treatment which will
provide them higher traction in the market during the forecast period.
FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the Global Liquid Biopsy Market by Biomarker
Type, by End-User, and by Region
• To cater comprehensive information on factors impacting market growth (drivers,
restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe,
Asia Pacific, Latin America, and Rest of the World
• To record evaluate and competitive landscape mapping- product launches, technological
advancements, mergers and expansions
• Profiling of companies to evaluate their market shares, strategies, financials and core
competencies
Inquire further details about this report at: [email protected]
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised
solutions for our clients. Through in-depth market insights and consultancy, we present our
clients with the tools they need to be at the forefront of their industry – a position secured for
far more than the near future.
Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: [email protected]
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com